NCT06435468 Biocollection of Rare Pediatric-onset of Autoimmune and Autoinflammatory Diseases

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 400 participants in total. It began in 2025-02-26 with a primary completion date of 2035-02-27.

Brief Summary

Rare diseases are defined as those that affect one person in 2,000, or around three million people in France. The majority of rare diseases are caused by genetics and tend to be severe when they begin in childhood. Autoimmune and autoinflammatory diseases, such as systemic lupus, juvenile dermatomyositis, and juvenile idiopathic arthritis, are examples of rare pediatric diseases. While autoimmune diseases are characterized by an inappropriate adaptive immune response, autoinflammatory diseases involve an excess of the innate immune response. The precise mechanisms of these diseases are not yet fully understood, but recent research has led to advances in their diagnosis and identification, particularly in early onset and familial forms. However, the rarity of these diseases and limited availability of biological samples pose significant challenges. This study aims to create a biological collection, which includes primary cells (PBMC), DNA, RNA, lymphoblastic lines, and serum, that will help identify genetic and immunological abnormalities in rare autoimmune and autoinflammatory diseases through various research projects.

Eligibility Criteria

Inclusion Criteria: * Patients * minor or adult patient of any age with a rare dysimmune disease characterized by autoimmunity or auto-inflammation or early lymphoproliferation, having started in childhood (\<18 years), or syndromic or familial * relative of a minor or adult patient with a rare dysimmune disease characterized by autoimmunity or auto-inflammation or early lymphoproliferation, having started in childhood (\<18 years of age) or syndromic or familial, * weight greater than 5 kg * Patient/parents/guardians who were informed of the study and signed the consent form. * patient affiliated to a social security scheme Healthy volunteer participants * minor or adult participants with no age restrictions * weight over 5 kg * Subject /Parents/guardians who were informed of the study and signed a consent form. * Patient affiliated to a social security scheme Exclusion Criteria: Patients \- Subjects /Parents/guardians, refusing to participate in the study Healthy volunteer participants : * active infection (viral, bacterial, parasitic) * history of neoplasia (\< 5 years) or current neoplasia * participants with a personal or family history of autoimmune disease * immunocompromised participant (immune deficiency or transplant recipient) * Subjects/parents/guardians refusing to participate in the study * Adults under legal protection (guardianship, curatorship)

Contact & Investigator

Frequently Asked Questions

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.